Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$838K Hold
3,329
0.02% 352
2026
Q1
$724K Sell
3,329
-6,886
-67% -$1.53M 0.02% 364
2025
Q4
$2.33M Buy
10,215
+3,834
+60% +$873K 0.06% 249
2025
Q3
$1.48M Buy
6,381
+338
+6% +$68.8K 0.04% 303
2025
Q2
$1.12M Sell
6,043
-782
-11% -$145K 0.03% 328
2025
Q1
$1.4M Sell
6,825
-1,618
-19% -$315K 0.05% 304
2024
Q4
$1.5M Buy
+8,443
New +$1.55M 0.04% 298

Other funds holding ABBV

Avanza Fonder's ABBV Position: Q2 2026 in Review

Avanza Fonder held its AbbVie (ABBV) position steady in Q2 2026 at 3,329 shares worth $838K. The position accounts for 0.02% of the portfolio, ranked #352.

Avanza Fonder first reported a position in ABBV in Q4 2024 and has held it in 7 quarters since. The position peaked at $2.33M in Q4 2025. 1,743 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Avanza Fonder held 3,329 shares of AbbVie worth $838K as of Q2 2026.
  • Avanza Fonder left its AbbVie share count unchanged in Q2 2026.
  • AbbVie made up 0.02% of Avanza Fonder's portfolio in Q2 2026, its #352 holding.
  • Avanza Fonder first reported a position in AbbVie in Q4 2024 and has held it in 7 quarters since.
  • Avanza Fonder's AbbVie position peaked at $2.33M in Q4 2025.
  • 1,743 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Avanza Fonder's 13F filing for Q2 2026, filed 17 Jul 2026.